Histological profile of tumours from MYCN transgenic mice

Journal of Clinical Pathology

Volumn 61, Issue 10, 2008, Pages 1098-1103

  Moore, H C ^a   Wood, K M ^b   Jackson, M S ^c   Lastowska, M A ^c   Hall, D ^c   Imrie, H ^a   Redfern, C P F ^a   Lovat, P E ^a   Ponthan, F ^a   O'Toole, K ^a   Lunec, J ^a   Tweddle, D A ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC HETEROGENEITY; HISTOLOGY; HISTOPATHOLOGY; HOMOZYGOSITY; IMMUNOCYTOCHEMISTRY; MALE; MOUSE; NEUROBLASTOMA; NONHUMAN; ONCOGENE; ONCOGENE MYCN; PRIORITY JOURNAL; TRANSGENIC MOUSE; TRANSGENICS;

ABDOMINAL NEOPLASMS; ANIMALS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MICE; MICE, TRANSGENIC; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; UBIQUITIN THIOLESTERASE;

EID: 53649092954     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2007.054627     Document Type: Article

References (28)

1. Brodeur GM, Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-16.
2. Shimada H, Ambros IM, Dehner LP, et al. Terminology and morphologic criteria of neuroblastic tumours. Cancer 1999;86:349- 63.
3. Seeger RC, Wada R, Brodeur GM, et al. Expression of N-myc by neuroblastomas with one or more multiple copies of the oncogene. Prog Clin Biol Res 1988;271:41-9.
4. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111-6.
5. Chan HSL, Gallie BL, DeBoer PS, et al. MYCN protein expression as a predictor or neuroblastoma prognosis. Clin Can Res 1997;3:1699-706.
6. Kohl NE, Kanda N, Schrech RR. Transposition and amplification of oncogene-related sequences in human neuroblastoma. Cell 1983;35:359-67.
7. Schwab M, Varmus HE, Bishop JM. Human gene N-myc contributes to neoplastic transformation of mammalian cells in culture. Nature 1985;316:160-2.
8. Cohn SL, Tweddle DA. MYCN amplification remains prognostically strong 20 years after its 'clinical debut'. Eur J Cancer 2004;40:2639-42.
9. Weiss WA, Aldape K, Mohapatra G, et al. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 1997;16:2985-95.
10. Dyer MA, Mouse models of childhood cancer of the nervous system. J Clin Pathol 2004;57:561-76.
11. Hansford LM, Thomas WD, Keating JM, et al. Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. Proc Natl Acad Sci USA 2004;101:12664-9.
12. Bomken SN, Redfern K, Wood KM, et al. Limitations in the ability of NB84 to detect metastatic neuroblastoma cells in bone marrow. J Clin Pathol 2006;59:927-9.
13. Tweddle DA, Malcolm AJ, Cole M, et al. p53 cellular localisation and function in neuroblastoma: evidence for defective G1 arrest despite WAF1 induction in MYCN- amplified cells. Am J Pathol 2001;158:2067-77.
14. Wada RK, Seeger RC, Brodeur GM. Characterisation of human neuroblastoma cell lines that lack N-myc gene amplification. Prog Clin Biol Res 1988;271:57-69.
15. Cheng AJ, Ching Cheng N, Ford J, et al. Cell lines from MYCN transgenic murine tumours reflect the molecular and biological characteristics of human neuroblastoma. Eur J Cancer 2007;43:1467- 75.
16. Joshi W, Rao RV, Cantor AB, et al. Modified histologic grading of neuroblastoma by replacement of mitotic rate with mitosis karyorrhexis index: a clinicopathological study of 223 cases from the Paediatric Oncology Group. Cancer 1996;77:1582-8.
17. Shimada H, Stram DO, Chatten J, et al. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. J Natl Cancer Inst 1995;87:1470-6.
18. Goto S, Umehara S, Gerbing RB, et al. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumours: a report from the Children's Cancer Group. Cancer 2001;92:2699-708.
19. Umehara S, Nakagawa A, Matthay KK, et al. Histopathology defines prognostic subsets of ganglioneuroblastoma, nodular. Cancer 2000;89:1150-61.
20. Ferry JA, Burkitt's lymphoma: clinopathological features and differential diagnosis. Oncologist 2006;11:375-83.
21. Cooper R, Khakoo Y, Matthay KK, et al. Opsoclonus- myoclonus-ataxia syndrome in neuroblastoma: histopathologic features-a report from the Children's Cancer Group. Med Pediatr Oncol 2001;36:623-9.
22. Gambini C, Conte M, Bernini G, et al. Neuroblastic tumours associated with opsoclonus-myoclonus syndrome: histological, immunohistochemical and molecular features of 15 Italian cases. Virchows Arch 2003;442:555-62.
23. Rudolph P, Lappe T, Hero B, et al. Prognostic significance of the proliferative activity in neuroblastoma. Am J Pathol 1997;150:133-45.
24. Krams M, Hero B, Berthold F, et al. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification. Cancer 2002;94:854-61.
25. Thiele CJ, Reynolds CP, Israel MA. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 1985;313:404-6.
26. Nara K, Kusafuka T, Yoneda A, et al. Silencing of MYCN by RNA interference induces growth inhibition, apoptotic activity and cell differentiation in a neuroblastoma cell line with MYCN amplification. Int J Oncol 2007;30:1189-96.
27. Kang JH, Rychahou PG, Ishola TA, et al. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells. Biochem Biophys Res Commun 2006;351:192-7.
28. Wenzel A, Cziepluch C, Hamann U, et al. The N-Myc oncoprotein is associated in vivo with the phosphoprotein Max (p20/22) in human neuroblastoma cells. EMBO J 1991;10:3703-12.